Structure Therapeutics, also known as GPCR, has seen significant stock movement, with some outlets reporting sharp swings and a strong one-year return. The company's obesity drug, including a pill that helped patients lose weight, has been a focus of attention, with some analysts raising the stock's price target. Comparisons are being made with other companies, such as Novo Nordisk, in terms of investment potential in the obesity treatment sector.